NCT02687152View on ClinicalTrials.gov

Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

January 31, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
OTHER

N-hydroxy-nor-L-arginine

Trial Locations (1)

17176

Karolinska Institutet, Stockholm

All Listed Sponsors
lead

Karolinska Institutet

OTHER

NCT02687152 - Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes | Biotech Hunter | Biotech Hunter